SHANGHAI JUNSHI BIO YC1 Total Assets
SHANGHAI JUNSHI BIO YC1 total assets. Based on the latest financial reports, SHANGHAI JUNSHI BIO YC1 (8SJ) holds total assets worth €12.40 Billion EUR (≈ $14.50 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 8SJ stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of SHANGHAI JUNSHI BIO YC1 (2021–2025)
Total assets of SHANGHAI JUNSHI BIO YC1 from 2021 to 2025. This chart illustrates how SHANGHAI JUNSHI BIO YC1's total assets have evolved over time, based on quarterly financial data. See 8SJ share price today for real-time trading data and today's change.
SHANGHAI JUNSHI BIO YC1 - Asset Composition Analysis
SHANGHAI JUNSHI BIO YC1 Total Assets Breakdown (December 2025)
SHANGHAI JUNSHI BIO YC1 total assets breakdown as of December 2025. SHANGHAI JUNSHI BIO YC1's total assets of €12.40 Billion consist of 36.0% current assets and 64.1% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 20.9% |
| Accounts Receivable | €506.44 Million | 4.1% |
| Inventory | €573.11 Million | 4.6% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €170.52 Million | 1.4% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how SHANGHAI JUNSHI BIO YC1's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of SHANGHAI JUNSHI BIO YC1 to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SHANGHAI JUNSHI BIO YC1's current assets represent 36.0% of total assets in 2025, a decrease from 52.8% in 2021.
- Cash Position: Cash and equivalents constituted 20.9% of total assets in 2025, down from 31.7% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2021.
- Asset Diversification: The largest asset category is inventory at 4.6% of total assets.
SHANGHAI JUNSHI BIO YC1 Competitors by Total Assets
Key competitors of SHANGHAI JUNSHI BIO YC1 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL LTD SPON.ADR 2
F:CSJA
|
Germany | €38.45 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
PHARVARIS N.V. EO -12
F:9EN
|
Germany | €301.45 Million |
|
NANOBIOTIX S.A. SP.ADR
F:5NRA
|
Germany | €67.76 Million |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513
|
China | CN¥3.82 Billion |
SHANGHAI JUNSHI BIO YC1 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.59 | 2.07 | 2.07 |
| Quick Ratio | 1.38 | 1.83 | 1.83 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €1.65 Billion | €2.49 Billion | €2.49 Billion |
SHANGHAI JUNSHI BIO YC1 - Advanced Valuation Insights
This section examines the relationship between SHANGHAI JUNSHI BIO YC1's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.57 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | 14.8% |
| Total Assets | €12.40 Billion |
| Market Capitalization | $526.46 Million USD |
Valuation Analysis
Below Book Valuation: The market values SHANGHAI JUNSHI BIO YC1's assets below their book value (0.04x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: SHANGHAI JUNSHI BIO YC1's assets grew by 14.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for SHANGHAI JUNSHI BIO YC1 (2021–2025)
The table below shows the annual total assets of SHANGHAI JUNSHI BIO YC1 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €12.40 Billion ≈ $14.50 Billion |
+14.80% |
| 2024-12-31 | €10.80 Billion ≈ $12.63 Billion |
-4.95% |
| 2023-12-31 | €11.36 Billion ≈ $13.28 Billion |
-9.65% |
| 2022-12-31 | €12.58 Billion ≈ $14.70 Billion |
+13.81% |
| 2021-12-31 | €11.05 Billion ≈ $12.92 Billion |
-- |
About SHANGHAI JUNSHI BIO YC1
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China. The company's product pipelines include Tifcemalimab, an anti- B and T lymphocyte attenuator mAB which is in phase III clinical trial to treat lung cancer and lymphocyte; Roconkibart, an anti-interleukin-17A monoclonal antibody which is in pha… Read more